ABBV.US
ABBV.US

Last Day

Drug Manufacturers – General

Latest Valuation

  • Trailing PE:
  • Forward PE:
  • Price Sales TTM:
  • Price Book MRQ:
  • Enterprise Value:
  • Enterprise Value Revenue:
  • Enterprise Value Ebitda:
  • Beta:

Key Highlights

  • Shares Outstanding:
  • Market Capitalization:
  • Market Capitalization Mln:
  • EBITDA:
  • PE Ratio:
  • PEG Ratio:
  • Wall Street Target Price:
  • Book Value:
  • Dividend Share:
  • Dividend Yield:
  • Earnings Share:
  • EPS Estimate Current Year:
  • EPS Estimate Next Year:
  • EPS Estimate Next Quarter:
  • EPS Estimate Current Quarter:
  • Most Recent Quarter:
  • Profit Margin:
  • Operating Margin TTM:
  • Return On Assets TTM:
  • Return On Equity TTM:
  • Revenue TTM:
  • Revenue Per Share TTM:
  • Quarterly Revenue Growth YOY:
  • Gross Profit TTM:
  • Diluted Eps TTM:
  • Quarterly Earnings Growth YOY:

Basic Information

  • Type:
  • Name:
  • Exchange:
  • Currency Code:
  • Currency Name:
  • Currency Symbol:
  • Country Name:
  • Fiscal Year End:
  • IPO Date:
  • International Domestic:
  • Sector:
  • Industry:
  • Address:
  • Country:
  • Listings:
  • Web URL:
  • Full Time Employees:
  • Updated At:
  • Gic Sector:
  • Gic Group:
  • Gic Industry:
  • Gic SubIndustry:

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet’s diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn’s disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson’s disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. Address: 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400

2024-6-30